See Shionogi-Sponsored Publications
Publications
Here, you can review available Shionogi-sponsored publications. If you would like an electronic copy of one of the journal publications on this page, please contact
Shionogi Medical Information for further assistance.
Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses of products will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Pharmacokinetics, safety and tolerability of single-dose or multiple-dose cefiderocol in hospitalized pediatric patients three months to less than eighteen years old with infections treated with standard-of-care antibiotics in the PEDI-CEFI phase 2 study
Pharmacokinetics, safety and tolerability of single-dose or multiple-dose cefiderocol in hospitalized pediatric patients three months to less than eighteen years old with infections treated with standard-of-care antibiotics in the PEDI-CEFI phase 2 study
Effectiveness and safety of cefiderocol in clinical practice for treatment of patients with Gram-Negative bacterial infections: US interim results of the PROVE Study
Effectiveness and safety of cefiderocol in clinical practice for treatment of patients with Gram-Negative bacterial infections: US interim results of the PROVE Study
Efficacy and safety of 5-Day oral ensitrelvir for patients with mild-to-moderate COVID-19: The SCORPIO-SR randomized clinical trial
Efficacy and safety of 5-Day oral ensitrelvir for patients with mild-to-moderate COVID-19: The SCORPIO-SR randomized clinical trial
Efficacy and safety of ensitrelvir for asymptomatic or mild COVID-19: An exploratory analysis of a multicenter, randomized, phase 2b/3 clinical trial
Efficacy and safety of ensitrelvir for asymptomatic or mild COVID-19: An exploratory analysis of a multicenter, randomized, phase 2b/3 clinical trial
In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals
In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals